NextCure (NXTC) Q3 2026 earnings summary

Executive summary

• Strategic focus shifted to completing the proposed Avere merger, supporting remaining agreements and monetizing legacy assets after sponsored clinical development wound down.

• The S-4 became effective November 6, 2026; the stockholder vote was scheduled for December 9, subject to approval and customary closing conditions.

• Restructuring and the LNCB74 transfer reduced future operating cash requirements.

Financial highlights

• Q3 2026 net loss was $6.8M vs. $8.6M in Q3 2025; 9M net loss was $31.5M vs. $46.4M.

• Q3 operating expenses were $6.9M vs. $8.9M; 9M operating expenses were $32.1M vs. $47.9M.

• Q3 net loss improvement reflected lower R&D and $2.0M of net restructuring gains, partly offset by higher G&A.

• Cash, cash equivalents and marketable securities were $8.7M at September 30, 2026, down from $41.8M at December 31, 2025.

Outlook and guidance

• Existing cash was expected to fund operations into early 2027; future losses and uncertainty over merger completion raised substantial doubt about continuing as a going concern.

• Research spending was expected to remain well below historical levels, with costs focused on transition support, contractual obligations, IP maintenance and legacy-asset monetization.

• Approximately $820M in committed merger financing is intended to fund Avere’s AVR-001 development and future combined-company operations.

• Subject to approval and customary conditions, the combined company was expected to operate as Avere and trade on Nasdaq as AVRX; existing stockholders were expected to retain a minority stake and receive contingent value rights tied to specified legacy assets.